Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Indivior Pharmaceuticals, Inc. (INDV) Institutional Ownership & Insider Trading

336 institutions reported holding Indivior Pharmaceuticals, Inc. shares in 13F filings for the quarter ended 2026-06-30, according to EquiReason's reading of their SEC filings. 13 insider trades on Form 4 since 2025-10-01.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

INDVIndivior Pharmaceuticals, Inc.Follow INDV — free
Drug Manufacturers - Specialty & Generic · Healthcare
—
Price chart with a free account
Market cap
4.1B
P/E TTM
12.4
Dividend yield
—
52-week
—
Next earnings
29 Oct, in 5 days

Institutions · all 13F filers

quarter to 30 Jun 2026 · filers in both quarters

336 institutions held —% of the shares. Across filers that reported both quarters, shares held changed -3.7%.

Increased+107New+75Decreased-102Closed-29

Largest moves, shares (millions)

Franklin Resources+3.2MAssenagon Asset Management…+3.1MPoint72 Asset Management+1.2MMillennium Management-2.5MGoldman Sachs Group-1.7MDeerfield Management Company-1.4M

Institutional flow by quarter

net shares added or trimmed, millions · filers in both quarters
+0.0Dec 25+0.0Mar 26-4.7Jun 26
QuarterHoldersShares held, MChangeIncreasedNewDecreasedClosed
Jun 26336123-3.7%1077510229
Mar 26288128—————
Dec 25119—————

Indivior Pharmaceuticals, Inc. — questions

Who owns Indivior Pharmaceuticals, Inc. stock?
336 institutions reported Indivior Pharmaceuticals, Inc. shares in 13F filings for the quarter ended 2026-06-30. The largest: BlackRock, Inc. (15.8%), VANGUARD PORTFOLIO MANAGEMENT LLC (6.4%), OAKTREE CAPITAL MANAGEMENT LP (5.2%).
Are Indivior Pharmaceuticals, Inc. insiders buying or selling?
13 insider trades on Form 4 since 2025-10-01; the full list, with dates, people and plan status, is on this page.

Every figure on this page comes from Indivior Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.